Among mol-GBMs, 60% were upgraded from WHO grade 3 IDH-wildtype anaplastic astrocytomas, and the other 40% originated from WHO grade 2 IDH-wildtype diffuse astrocytomas. This evidence concerns the gene IDH2 and diffuse astrocytoma.